Get the Stockscreener App
5.14
0.19%
-0.01
Radiopharm Theranostics Ltd Adr stock is traded at $5.14, with a volume of 24,134.
It is down -0.19% in the last 24 hours and down -14.19% over the past month.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
See More
Previous Close:
$5.15
Open:
$5.06
24h Volume:
24,134
Relative Volume:
0.04
Market Cap:
$40.52M
Revenue:
$2.34M
Net Income/Loss:
$-24.85M
P/E Ratio:
-1.4817
EPS:
-3.4691
Net Cash Flow:
$-23.25M
1W Performance:
-0.19%
1M Performance:
-14.19%
6M Performance:
+15.51%
1Y Performance:
-0.96%
1-Day Range:
$5.03
$5.225
1-Week Range:
$4.94
$5.30
52-Week Range:
$3.4962
$16.25
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Name
Radiopharm Theranostics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare RADX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
5.14 | 40.60M | 2.34M | -24.85M | -23.25M | -3.4691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Stock (RADX) Latest News
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Radiopharm Theranostics LimitedSponsored ADR (NASDAQ:RADX) Sees Large Increase in Short Interest - MarketBeat
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic - TipRanks
RAD Increases Ownership in Radiopharm Ventures to 87.5% - GlobeNewswire Inc.
RAD Increases Ownership in Radiopharm Ventures to 87.5% - Sahm
RADX: Interim Readout Achieves 92% Concordance - Research Tree
Equities Analysts Issue Forecasts for RADX FY2026 Earnings - Defense World
RADX FY2026 EPS Reduced by Brookline Capital Management - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Radiopharm Theranostics Limited Sponsored ADR (RADX), Novan (NOVN) - The Globe and Mail
Radiopharm Theranostics (NASDAQ:RADX) Receives Buy Rating from B. Riley - Defense World
Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com UK
Radiopharm Theranostics (NASDAQ:RADX) Earns "Buy" Rating from B. Riley - MarketBeat
Dow Falls 50 Points; US Adds 64,000 Jobs In November - Benzinga
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
US stock market crash today: Dow, S&P 500, Nasdaq slide deep into the red — why is the stock market down today? - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com India
Radiopharm (RADX) Sees Slight Pessimism From Analysts - Finviz
US stock market crash today: Dow, S&P 500, Nasdaq slide deep into the red — why is the stock market down t - The Economic Times
Radiopharm Theranostics interim data shows 92% reach endpoint in RAD101 study - Investing.com Canada
Radiopharm Theranostics stock soars after positive brain metastases trial data - Investing.com
Radiopharm Theranostics stock soars after positive brain metastases trial data By Investing.com - Investing.com India
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - Sahm
Book value per share of Radiopharm Theranostics Limited Sponsored ADR – NASDAQ:RADX - TradingView — Track All Markets
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
Radiopharm Theranostics Announces Successful General Meeting Resolutions - TipRanks
Radiopharm Theranostics announces successful general meeting resolutions - MSN
B. Riley Lowers Radiopharm Theranostics (NASDAQ:RADX) Price Target to $13.00 - Defense World
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
B. Riley Securities Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer - Sahm
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC) - The Globe and Mail
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Globe and Mail
Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Resolutions - MSN
Radiopharm Theranostics Limited: Promising Financial and Clinical Outlook Justifies Buy Rating - TipRanks
Radiopharm (ASX:RAD, Nasdaq:RADX) to Showcase Oncology Pipeline at Deutsche Bank ADR Conference - Kalkine Media
Radiopharm Theranostics to Present at Deutsche Bank ADR Virtual Investor Conference - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Globe and Mail
B. Riley Securities Sticks to Its Buy Rating for Radiopharm Theranostics Limited Sponsored ADR (RADX) - The Globe and Mail
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
Radiopharm Theranostics Announces November AGM with Key Resolutions - MSN
Radiopharm Theranostics Ltd Adr Stock (RADX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):